Omvik P, Lund-Johansen P
Department of Cardiology, Haukeland Hospital, Bergen, Norway.
Cardiovasc Drugs Ther. 1993 Apr;7(2):193-206. doi: 10.1007/BF00878508.
Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure. Antihypertensive agents may, therefore, reduce blood pressure through widely different actions and, at the same time, elicit counterregulatory responses. This is a review of the long-term hemodynamic effects at rest as well as during exercise of nine relatively new antihypertensive compounds: a beta-blocker (epanolol), an alpha-receptor blocker (doxazosin), two double-acting compounds (dilevalol and carvedilol), three calcium antagonists (amlodipine, felodipine, and diltiazem), an angiotensin-converting enzyme inhibitor (lisinopril), a serotonin antagonist (ketanserin), and low-salt diet as a nonpharmacological treatment in 171 patients with mild to moderate essential hypertension. The results in the treatment groups are compared to the hemodynamic changes seen in 28 hypertensive patients left untreated for 10 years. The patient populations of the different groups were comparable. The invasive hemodynamic technique, including intraarterial blood pressure recording and measurements of cardiac output by Cardigreen, was the same in all studies. While blood pressure remained nearly unchanged in the untreated group, all antihypertensive compounds induced significant and sustained blood pressure reduction both at rest and during exercise. The modest reduction (3-5%) in blood pressure during a low-salt diet was also statistically significant. This review shows the multiplicity of the long-term hemodynamic changes, ranging from a reduction in cardiac output to peripheral vasodilatation, during chronic antihypertensive therapy. In untreated hypertensives, the cardiac output is reduced by 1-2% per year and total peripheral resistance is increased by 2-3% per year. The review also focuses on counterregulatory responses and modify the initial reduction in blood pressure after drug treatment for hypertension. It is concluded that proper understanding of the hemodynamic effects of antihypertensive agents is useful in the selection of the right treatment for specific groups of hypertensive patients.
高血压是由于众多已知和未知机制之间复杂的相互作用紊乱所致,这些机制通常控制着血压。因此,抗高血压药物可能通过广泛不同的作用来降低血压,同时引发反调节反应。本文综述了九种相对较新的抗高血压化合物在静息和运动时的长期血流动力学效应:一种β受体阻滞剂(依泮洛尔)、一种α受体阻滞剂(多沙唑嗪)、两种双作用化合物(地来洛尔和卡维地洛)、三种钙拮抗剂(氨氯地平、非洛地平和地尔硫䓬)、一种血管紧张素转换酶抑制剂(赖诺普利)、一种5-羟色胺拮抗剂(酮色林),以及低盐饮食作为171例轻度至中度原发性高血压患者的非药物治疗方法。将治疗组的结果与28例未经治疗长达10年的高血压患者的血流动力学变化进行了比较。不同组的患者群体具有可比性。所有研究中采用的有创血流动力学技术相同,包括动脉内血压记录和通过Cardigreen测量心输出量。在未治疗组中血压几乎保持不变的情况下,所有抗高血压化合物在静息和运动时均能显著且持续地降低血压。低盐饮食期间血压的适度降低(3 - 5%)在统计学上也具有显著性。本综述表明,在慢性抗高血压治疗期间,长期血流动力学变化具有多样性,范围从心输出量降低到外周血管扩张。在未经治疗的高血压患者中,心输出量每年降低1 - 2%,总外周阻力每年增加2 - 3%。本综述还关注反调节反应以及高血压药物治疗后对初始血压降低的影响。得出的结论是,正确理解抗高血压药物的血流动力学效应有助于为特定高血压患者群体选择合适的治疗方法。